< >


PRAGMA Therapeutics is a French biotech company, dedicated to the discovery and development of novel treatments for stress related disorders, in particular for Hearing disorders and Post-Traumatic Stress Disorders. Founded in 2015, PRAGMA is a flexible organization led by an experienced team of international neuroscience leaders, and developing proprietary small molecules that normalize glutamate functions.

Targeting mGlu7 receptor for PTSD and HEARING LOSS

Hearing Loss may develop slowly over many years or set in acutely (e.g. following some noise or head trauma). It may be either due to insufficient sound conduction from the outer to the inner ear or much more frequently to damage to the hair cells and neurons in the cochlea or to the auditory nerve. Post-Traumatic Stress Disorder is a psychiatric disorder which can develop following exposure to a traumatic event (e.g., combat exposure, terrorist attack, car crash), and is characterized by altered fear-related learning and extinction related to glutamate dysfunction in trauma-related brain regions. PRAGMA Therapeutics develops innovative medicines through modulation of the metabotropic glutamate receptor subtype 7 (mGlu7) for the treatment of these two severe debilitating conditions affecting both civilian and military populations.